share_log

Poly (ADP-Ribose) Polymerase Inhibitors Pipeline Research Report 2021: Comprehensive Insights About 20+ Companies and 20+ Pipeline Drugs - ResearchAndMarkets.com

Poly (ADP-Ribose) Polymerase Inhibitors Pipeline Research Report 2021: Comprehensive Insights About 20+ Companies and 20+ Pipeline Drugs - ResearchAndMarkets.com

Poly(ADP-Ribose)聚合酶抑制剂管道研究报告2021年:对20多家公司和20多种管道药物的综合洞察-Research andMarkets.com
Businesswire ·  2021/11/30 19:10

DUBLIN--(BUSINESS WIRE)--The "Poly (ADP-Ribose) Polymerase Inhibitors - Pipeline Insight, 2021" drug pipelines have been added to ResearchAndMarkets.com's offering.

都柏林--(美国商业新闻网)--“Poly(ADP-Ribose)聚合酶抑制剂--管道洞察,2021年”药物管道被添加到Research andMarkets.com的献祭。


This "Poly (ADP-ribose) polymerase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Poly (ADP-ribose) polymerase inhibitors pipeline landscape.

这份名为“聚(ADP-核糖)聚合酶抑制剂--管道洞察,2021年”的报告提供了有关聚(ADP-核糖)聚合酶抑制剂的20多家公司和20多种流水线药物的全面见解。

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

它涵盖了流水线药物概况,包括临床和非临床阶段的产品。它还包括按产品类型、阶段、给药途径和分子类型进行的治疗评估。它进一步突显了这一领域不活跃的管道产品。

Report Highlights

报告要点

The companies and academics are working to assess challenges and seek opportunities that could influence Poly (ADP-ribose) polymerase inhibitors R&D. The therapies under development are focused on novel approaches for Poly (ADP-ribose) polymerase inhibitors.

这些公司和学者正在努力评估挑战,寻找可能影响聚(ADP-核糖)聚合酶抑制剂研发的机会。正在开发的疗法集中在针对聚(ADP-核糖)聚合酶抑制剂的新方法上。

Poly (ADP-ribose) polymerase inhibitors Emerging Drugs Chapters

聚(ADP-核糖)聚合酶抑制剂新药分会

This segment of the Poly (ADP-ribose) polymerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

多聚(ADP-核糖)聚合酶抑制剂报告的这一部分包含了对临床开发不同阶段的各种药物的详细分析,包括第三阶段、第二阶段、第一阶段、临床前和发现阶段。它还有助于理解临床试验的细节、表达的药理作用、协议和合作,以及最新的新闻和新闻稿。

Poly (ADP-ribose) polymerase inhibitors Emerging Drugs

聚(ADP-核糖)聚合酶抑制剂新药

Talazoparib: Pfizer

他唑帕利:辉瑞

Talazoparib is an investigational anticancer drug called a PARP (poly ADP ribose polymerase) inhibitor, which is being evaluated in breast cancer patients with germline BRCA (gBRCA) mutations, as well as other cancer types with deficiencies in DNA damage repair (DDR). Talazoparib has not been approved by any Regulatory Authorities for the treatment of any disease. As a dual-mechanism PARP inhibitor, talazoparib is believed to both inhibit and trap the PARP enzyme, which may lead to heightened cell death.

他唑巴利布是一种名为PARP(聚ADP核糖聚合酶)抑制剂的研究用抗癌药物,目前正在对具有种系BRCA(GBRCA)突变的乳腺癌患者以及DNA损伤修复(DDR)缺陷的其他癌症类型进行评估。他唑帕利尚未获得任何监管部门的批准,用于治疗任何疾病。作为一种双机制的PARP抑制剂,他唑帕利被认为既能抑制PARP酶,又能捕获PARP酶,从而可能导致细胞死亡加剧。

Niraparib: Janssen

尼亚帕里布:扬森

Niraparib is an orally-administered selective PARP inhibitor that is currently being studied by Janssen for the treatment of patients with prostate cancer. In April 2016, Janssen entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc., for exclusive rights to niraparib in prostate cancer.

Niraparib是一种口服的选择性PARP抑制剂,目前Janssen正在研究用于前列腺癌患者的治疗。2016年4月,Janssen与TESARO,Inc.签订了一项全球(日本除外)合作和许可协议,以获得治疗前列腺癌的niraparib的独家权利。

In the U.S., niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Niraparib is currently marketed as ZEJULA by TESARO, an oncology-focused business within GSK, devoted to providing transformative therapies to people facing cancer.

在美国,niraparib用于成人复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌的维持性治疗,这些患者对铂类药物的化疗完全或部分有效。Niraparib目前由TESARO销售,名称为ZEJULA。TESARO是葛兰素史克公司内一家专注于肿瘤学的企业,致力于为面临癌症的人提供变革性疗法。

There are approx. 20+ key companies which are developing the Poly (ADP-ribose) polymerase inhibitors. The companies which have their Poly (ADP-ribose) polymerase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Pfizer.

大约有几种。20多家正在开发聚(ADP-核糖)聚合酶抑制剂的重点公司。他们的聚(ADP-核糖)聚合酶抑制剂候选药物处于最高级阶段(即第三阶段)的公司包括辉瑞(Pfizer)。

Key Questions Answered

回答的关键问题

  • How many companies are developing Poly (ADP-ribose) polymerase inhibitors drugs?
  • How many Poly (ADP-ribose) polymerase inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Poly (ADP-ribose) polymerase inhibitors?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Poly (ADP-ribose) polymerase inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Poly (ADP-ribose) polymerase inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?
  • 有多少公司在开发聚(ADP-核糖)聚合酶抑制剂药物?
  • 每家公司开发了多少种聚(ADP-核糖)聚合酶抑制剂药物?
  • 有多少新兴药物处于治疗聚(ADP-核糖)聚合酶抑制剂的中后期开发阶段?
  • 与聚(ADP-核糖)聚合酶抑制剂疗法相关的主要合作(工业-工业、工业-学术)、合并和收购、许可活动是什么?
  • 为克服现有疗法的局限性而开发的最新趋势、药物类型和新技术是什么?
  • 聚(ADP-核糖)聚合酶抑制剂的临床研究进展如何?
  • 被授予新兴药物的关键名称是什么?

Key Players

主要参与者

  • Pfizer
  • Janssen
  • Jiangsu HengRui Medicine
  • Jeil Pharmaceutical
  • Rhizen Pharmaceuticals
  • Rakovina Therapeutics
  • Ribon Therapeutics
  • Cybrexa Therapeutics
  • Waverley Pharma
  • Idience
  • IMPACT Therapeutics
  • Cephalon
  • Shanghai De Novo Pharmatech
  • Clovis Oncology
  • BeiGene
  • Abbvie
  • AstraZeneca
  • NanoGhost
  • Allarity Therapeutics
  • 辉瑞公司
  • 詹森
  • 江苏恒瑞医药
  • 杰尔制药公司
  • 瑞森制药(Rhizen PharmPharmticals)
  • 拉科维纳治疗公司
  • 丝带疗法
  • Cybrexa治疗学
  • 韦弗利制药公司
  • 学识
  • 影响治疗学
  • Cephalon
  • 上海德诺华药业公司(Shanghai De Novo Pharmatech)
  • 克洛维斯肿瘤学
  • 百济神州
  • 艾伯维
  • 阿斯利康
  • 纳米幽灵
  • Allarity治疗学

Key Products

重点产品

  • Talazoparib
  • Niraparib
  • Fluzoparib
  • Olaparib
  • Veliparib
  • Amelparib
  • RP 12146
  • CK 102
  • 2X-121
  • Pamiparib
  • NG 1002
  • SC 10914
  • Rucaparib
  • 他唑帕利
  • 尼拉帕利布
  • 氟唑帕利
  • 奥拉帕利
  • 维利帕利
  • 阿梅帕利布
  • RP 12146
  • CK 102
  • 2X-121
  • 帕米帕利布
  • NG1002
  • SC 10914
  • 鲁卡帕里布

Research programme: monoPARP inhibitors

研究计划:单PARP抑制剂

  • CBX 11
  • Senaparib
  • Venadaparib
  • CBX 11
  • 塞纳帕里布
  • 维那帕里布

For more information about this drug pipelines report visit

有关此药品管道报告的更多信息,请访问


Contacts
联系人

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

ResearchAndMarkets.com
劳拉·伍德(Laura Wood),高级新闻经理
邮箱:press@researchandmarket s.com
东部夏令时办公时间请拨打1-917-300-0470
美国/加拿大免费电话:1-800-526-8630
对于格林尼治标准时间办公时间,请致电+353-1-416-8900

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发